Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

November 10, 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

November 09, 2023

The mitigation and management of toxicities is a key component of treating patients with biliary tract cancers with targeted therapies.

November 03, 2023

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

November 03, 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

October 31, 2023

Expert oncologist Benjamin Levy, MD, shares data from the LIBRETTO-431 trial comparing selpercatinib to chemotherapy plus pembrolizumab in RET fusion-positive NSCLC following ESMO 2023.

October 27, 2023

A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.

October 27, 2023

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.

October 20, 2023

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

October 20, 2023

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

October 13, 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

October 13, 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

October 10, 2023

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

October 10, 2023

Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.

October 06, 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

October 06, 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

October 03, 2023

The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.

October 03, 2023

Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.

September 29, 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

September 29, 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

September 26, 2023

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.